A Phase 1, Open-Label, Multiple-Dose Study to Investigate the Comparability of the Pharmacokinetics of Orforglipron (LY3502970) Single Capsule and Multiple Capsules in Healthy Participants

The main purpose of this study is to assess and compare a single capsule and multiple capsules of Orforglipron based on the amount that gets into the blood stream and how long it takes the body to get rid of it, when given to healthy participants under fasted and fed conditions. How the body handles and eliminates the study drug after meals and on an empty stomach will be measured. Information about any adverse effects experienced will be collected and the safety and tolerability of Orforglipron will also be evaluated. The study will last approximately 21 weeks, including a screening period.

开始日期2024-12-01

申办/合作机构

Eli Lilly & Co.

NCT06672549 / Not yet recruiting临床3期

A Master Protocol for a Randomized, Controlled, Clinical Platform Trial to Investigate the Efficacy and Safety of Interventions for Chronic Weight Management in Pediatric Participants With Obesity or Overweight

The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

开始日期2024-12-01

申办/合作机构

Eli Lilly & Co.

100 项与 Orforglipron 相关的临床结果

登录后查看更多信息

100 项与 Orforglipron 相关的转化医学

登录后查看更多信息

100 项与 Orforglipron 相关的专利（医药）

登录后查看更多信息

项与 Orforglipron 相关的文献（医药）

2025-01-01·PHARMACOLOGICAL REVIEWS

Emerging pharmacotherapies for obesity: A systematic review

Article

作者: Al Rifai, Jana ; Valenzuela-Vallejo, Laura ; Rhayem, Caline ; Kokkorakis, Michail ; Mantzoros, Christos S ; Mantzoros, Christos S. ; Chakhtoura, Marlene ; Ghezzawi, Malak

The history of anti-obesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or Food and Drug Administration-approved weight loss medication, through searching Medline, Embase, and ClinicalTrials.gov (2012-2024). We identified 53 phase 3 and phase 2 trials, with 36 emerging anti-obesity drugs or combinations thereof and four withdrawn or terminated trials. Oral semaglutide 50 mg is the only medication that has completed a phase 3 trial. There are 14 ongoing phase 3 trials on glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) (ecnoglutide, orforglipron, TG103), GLP-1 RA/amylin agonist (CagriSema), GLP-1/glucagon RAs (mazdutide, survodutide), GLP-1/glucose-dependent insulinotropic polypeptide and glucagon RA (retatrutide), dapagliflozin, and the combination sibutramine/topiramate. Completed phase 2 trials on incretin-based therapies showed a mean percent weight loss of 7.4-24.2%. Almost half of the drugs undergoing phase 2 trials were incretin analogs. The obesity drug pipeline is expanding rapidly, with the most promising results reported with incretin analogs. Data on mortality and obesity-related complications, such as cardio-renal-metabolic events, are needed. Moreover, long-term follow-up data on the safety and efficacy of weight maintenance with novel obesity pharmacotherapies, along with studies focused on under-represented populations, cost-effectiveness assessments, and drug availability, are needed to bridge the care gap for patients with obesity. Significance Statement Obesity is the epidemic of the 21st century. Except for the newer injectable medications, drugs with suboptimal efficacy have been available in the clinician's armamentarium. However, emerging alternatives of novel agents and combinations populate the obesity therapeutic pipeline. This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.

2024-12-18·Science Translational Medicine

The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron

Article

作者: Willard, Francis S. ; Suter, Todd M. ; Emmerson, Paul J. ; Padgett, Leah R. ; Hewitt, Natalie ; White, Alex ; O’Farrell, Libbey S. ; Peterson, Jeffrey A. ; Sangwung, Panjamaporn ; Liu, Zhaomin ; Wainscott, David B. ; Coskun, Tamer ; Ruble, J. Craig ; Cox, Amy L. ; Sloop, Kyle W. ; Showalter, Aaron D. ; Snider, Brandy M. ; Coutant, David E. ; Dunbar, James D. ; Stutsman, Cynthia ; Woerly, Eric M. ; Ai, Minrong ; Droz, Brian A.

Orally bioavailable, synthetic nonpeptide agonists (NPAs) of the glucagon-like peptide-1 receptor (GLP-1R) may offer an effective, scalable pharmacotherapy to address the metabolic disease epidemic. One of the first molecules in the emerging class of GLP-1R NPAs is orforglipron, which is in clinical development for treating type 2 diabetes and obesity. Here, we characterized the pharmacological properties of orforglipron in comparison with peptide-based GLP-1R agonists and other NPAs. Competition binding experiments using either [ 125 I]GLP-1(7-36)NH 2 or [ 3 H]orforglipron indicated that orforglipron is a high-affinity [inhibition constant ( Ki ) = 1 nM], selective ligand of the human GLP-1R. Signal transduction assays showed that orforglipron has low intrinsic efficacy for effector activation and negligible β-arrestin recruitment. To evaluate GLP-1R engagement in vivo, mice expressing the human GLP-1R were administered orforglipron and subjected to a glucose tolerance test. Predicted receptor occupancy was calculated using the receptor Ki value of orforglipron and its unbound concentration in vivo that reduces hyperglycemia. These experiments revealed that low GLP-1R occupancy by orforglipron is sufficient to yield a full biological response. Moreover, in a model where CRISPR-Cas9 gene editing was used to sensitize the rat GLP-1R ( Glp1r S33W ) to GLP-1R NPAs, target engagement by orforglipron in the pancreas and brain was consistent with peptide-based GLP-1R agonists. Diet-induced obesity in Glp1r S33W rats enabled studies showing weight loss in animals orally administered orforglipron versus subcutaneous injection of GLP-1R agonist semaglutide. Furthermore, crossover studies indicated oral orforglipron can sustain efficacy initiated by parenteral semaglutide. The pharmacological properties of orforglipron may inform targeting of other peptide receptors with NPAs.

2024-12-01·METABOLISM-CLINICAL AND EXPERIMENTAL

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials

Review

作者: Li, Mengting ; Cao, Weiling ; Zheng, Guimei ; Deng, Weishang ; Xie, Zeyu ; Liang, Zhuoru

PURPOSE:

This study aimed to provide evidence-based support and a reference for the efficacy and safety of seven glucagon-like peptide-1 (GLP-1) receptor agonists and polyagonists for weight loss in patients with obesity or overweight through a network meta-analysis.

METHODS:

Relevant randomized controlled trials (RCTs) with an intervention duration of at least 16 weeks assessing seven GLP-1 receptor agonists and polyagonists (mazdutide, 6 or 4.5 mg; retatrutide, 12 or 8 mg; tirzepatide, 15 or 10 mg; liraglutide, 3.0 mg; semaglutide, 2.4 mg; orforglipron, 45 or 36 mg; and beinaglutide, 0.2 mg) in patient with obesity or overweight was searched using three databases (Cochrane Library, PubMed, and Embase) from creation to August 30, 2024. The primary outcome was the percentage change in body weight from baseline. Secondary outcomes included changes in waist circumference, hemoglobin A1c, and fasting plasma glucose level from baseline; adverse events, serious adverse events, adverse event withdrawal, and hypoglycemic events. We conducted a frequentist random-effects network meta-analysis to analyze the data extracted from the RCTs using Stata 16.1 software.

RESULTS:

Twenty-seven RCTs of seven GLP-1 receptor agonists and polyagonists and 15,584 patients were included in the network meta-analysis. In terms of efficacy, compared with placebo, retatrutide 12 mg (-22.10 % in body weight and - 17.00 cm in waist circumference), retatrutide 8 mg (-20.70 % and - 15.90 cm), and tirzepatide 15 mg (-16.53 % and - 13.23 cm) were the three most efficacious treatments for reducing body weight and waist circumference. However, these treatments were less effective in patients with type 2 diabetes mellitus (T2DM). In addition, patients with a high body mass index (BMI) or longer treatment cycles exhibited significantly greater weight loss than those with a low BMI or shorter treatment cycles. In terms of safety, patients without T2DM had a higher incidence of adverse events than those with T2DM. None of the interventions increased the incidence of serious adverse or hypoglycemic events (˂54 mg/dL). There was no significant difference in the incidence of adverse event withdrawal for all interventions in head-to-head comparisons. In addition, disparities in race, BMI, and treatment cycles did not significantly increase the incidence of adverse events. Finally, the sensitivity and publication bias analyses indicated that the basic analysis results were reliable.

CONCLUSION:

Retatrutide (both doses) and tirzepatide exhibited superior efficacy compared to other GLP-1 receptor agonists and polyagonists in reducing body weight and waist circumference. Patients without T2DM, those with a high BMI, and individuals undergoing longer treatment cycles demonstrated significantly greater weight loss and reductions in waist circumference. Dual or triple receptor agonists (GLP-1 plus glucose-dependent insulinotropic polypeptide and/or Glucagon receptor) are more effective for weight loss than GLP-1 receptor agonists.

281

项与 Orforglipron 相关的新闻（医药）

2025-01-03

·Endpoints

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

With the disappointment of Novo Nordisk’s injected CagriSema in obesity at the end of 2024, there are questions around how much more injected next-gen weight loss drugs can deliver above what’s already in the market. Consequently, there is heightened anticipation around oral products. And Eli Lilly, Novo’s main rival, has a major late-stage trial readout coming up. Lilly’s orforglipron, a GLP-1 agonist, is in various Phase 3 trials in patients with type 2 diabetes, obesity and both. But one study in patients with obesity but not diabetes, dubbed ATTAIN-1, will be watched particularly closely when data come in the second half of 2025. It is clear what the drug will have to achieve. Novo already has an oral GLP-1 on the market — Rybelsus, a once-daily pill formulation of semaglutide — though it’s only for diabetes so far. In its first Phase 3 trial in obesity, Rybelsus cut patients’ body weight by 15.1% after 68 weeks versus 2.4% with placebo. Following the release of these data in mid-2023, Novo said it would wait for results from another late-stage obesity trial before seeking approval for oral semaglutide in the condition. And those data arrived at the ObesityWeek meeting in November, with the pill allowing an average weight loss of 13.6% at 64 weeks compared with 2.2% for placebo. Novo has not said whether it has yet to file oral semaglutide for obesity. Whether orforglipron can exceed these two benchmarks when ATTAIN-1 reports its 72-week data later in 2025 remains to be seen. In the drug’s Phase 2 obesity trial, patients taking the highest dose at 45 mg once daily lost 14.7% of their weight, against 2.3% with placebo. But this was at 36 weeks, and if the effect deepens over time, it is possible that orforglipron could outdo oral semaglutide. Lilly has never explicitly said why it opted to develop an oral GLP-1 product over an oral form of tirzepatide, the subcutaneous blockbuster GIP/GLP-1 agonist sold as Zepbound for obesity. It is possible that the higher dose required for oral delivery could mean unmanageable side effects. Other possible explanations could be a simpler or cheaper manufacturing process for orforglipron than tirzepatide. The orforglipron readout will affect another company, too. The drug was licensed from Roche’s subsidiary Chugai, so the Swiss giant — which has a separate oral obesity candidate in early trials — could also see a return if orforglipron succeeds.

临床3期临床2期临床结果

2024-12-27

·echemi

Merck Halts TIGIT/LAG-3 Project, Shifts Focus to $2 Billion Oral GLP-1 Drug Collaboration

On December 16, Merck announced on its official website that it has officially stopped the development of the anti-TIGIT antibody Vibostolimab and the anti-LAG-3 antibody Favezelimab. This decision marks the end of Merck's years of effort in the field of immune checkpoint inhibitors. Two days later, on December 18, Merck announced its new strategic direction by reaching a collaboration agreement with domestic company Hansoh Pharmaceutical. According to the agreement, Merck will obtain global exclusive licensing rights for Hansoh’s oral small molecule GLP-1 receptor agonist HS-10535, while Hansoh will retain control of the drug in the Chinese market. The total amount of this collaboration is as high as $2 billion. This series of business adjustments reflects Merck's concerns about the impending patent cliff for its main product, Pembrolizumab (Keytruda). At the same time, these adjustments provide clues about future competitive focuses for innovative pharmaceutical companies. Vibostolimab, which Merck has discontinued, is an antibody drug targeting the TIGIT site. TIGIT is an inhibitory receptor expressed on T cells and NK cells, belonging to the immunoglobulin superfamily. Vibostolimab aims to block the TIGIT signaling pathway to enhance the body's immune response against tumor cells. Although TIGIT is regarded as a potential therapeutic target, Merck and several other pharmaceutical companies like Roche have conducted long-term development in this area but have not achieved success. Vibostolimab faced failures in multiple clinical trials, including the KeyVibe-002 trial in patients with metastatic non-small cell lung cancer (NSCLC) and studies in high-risk melanoma patients. Similarly, Merck's other drug Favezelimab is an antibody drug targeting the LAG-3 site, aiming to restore the effector function of T cells. Despite several clinical studies, including the Phase III KEYFORM-007 study in PD-L1 positive microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients, Favezelimab also failed to meet its primary endpoint, leading Merck to decide to terminate its clinical development program. After abandoning Vibostolimab and Favezelimab, Merck's next research focus shifts to the oral small molecule GLP-1 receptor agonist HS-10535. GLP-1 related products, as weight loss drugs, hold significant appeal for pharmaceutical companies. Novo Nordisk and Eli Lilly have already reaped substantial profits from their GLP-1 products. Merck began its layout in the GLP-1 project back in 2010, but has yet to successfully launch a product. This collaboration with Hansoh Pharmaceuticals may provide Merck with an opportunity to break through in this field. Currently, the oral Semaglutide tablet (Rybelsus) is the only marketed oral GLP-1 drug, utilizing SNAC technology to facilitate transcellular absorption through the gastric mucosa. Eli Lilly’s Orforglipron is leading the field of oral GLP-1 receptor agonists, while domestic companies such as Heng Rui Medicine's HRS-7535 and Wenshan Medicine's VCT220 are also actively developing. With the impending expiration of the Keytruda patent, Merck is under pressure to find its next blockbuster. Despite setbacks in the research of TIGIT, LAG-3, and GLP-1 targets, Merck's bet on oral GLP-1 small molecule drugs may provide it with a chance to overtake competitors.

引进/卖出临床3期免疫疗法抗体药物偶联物

2024-12-26

·CPHI制药在线

多年心血付诸东流后，默沙东押宝下一个竞争焦点

关注并星标CPHI制药在线 12月16日，默沙东在其官网宣布，正式终止其抗TIGIT抗体Vibostolimab和抗LAG-3抗体Favezelimab的开发，这一调整标志着默沙东在免疫检查点抑制剂领域的多年心血付诸东流。两天后，默沙东宣布押注的下一个目标。12月18日，默沙东宣布与国内翰森制药合作，默沙东将获得后者一款在研口服小分子GLP-1受体激动剂（GLP-1RA）HS-10535的全球独家许可权，翰森制药暂时保留HS-10535在中国的控制权，合作总金额高达20亿美元。频繁的业务调整背后，是默沙东对 K药（帕博利珠单抗）即将迎来专利悬崖的焦虑。而默沙东要押注的下一个竞争焦点，也为创新药企带来启发。 TIGIT、LAG-3靶点失利，多年心血打水漂此次默沙东终止开发的其中一款产品Vibostolimab，是一种抗TIGIT抗体。TIGIT是一种表达在T细胞和NK细胞上的抑制性受体，属于免疫球蛋白超家族。它可以与CD155和CD112等配体结合，从而抑制NK细胞和T细胞对肿瘤细胞的杀伤作用。因此，针对TIGIT的抗体或者其他药物可以用来阻断TIGIT信号通路，从而增强机体对肿瘤细胞的免疫反应，提高抗肿瘤活性。基于TIGIT这一作用机理，TIGIT靶点被视为下一个爆点，引来多家药企竞逐，但并没有药企成功。在TIGIT赛道，默沙东和罗氏是最积极开发的，两家药企已经坚持开发了八九年，双方竞逐多年，但都未修成正果。默沙东的Vibostolimab曾经历多次失败。 2023年12月，默沙东终止了KeyVibe-002试验，该试验旨在评估使用K药+Vibostolimab联合疗法与标准治疗多西他赛相比，在转移性NSCLC患者中的疗效。结果显示，与仅接受多西他赛治疗的患者相比，Vibostolimab+K药组未改善中位PFS和中位OS。 2024年5月，默沙东宣布终止正在进行的K药+Vibostolimab对比K药单药辅助治疗手术切除后的IIB-IV期高危黑色素瘤患者的研究。最终，基于现有的KeyVibe系列研究的全部数据，默沙东决定终止Vibostolimab的开发计划。另一个被终止研究的药物是抗LAG-3抗体Favezelimab，是默沙东自研的一款靶向淋巴细胞活化基因3（LAG-3）的抗体药物，旨在通过阻止LAG-3与其主要配体、主要组织相容性复合体（MHC）II类分子结合来恢复T细胞效应器功能。对于Favezelimab，默沙东开展了Favezelimab+K药复方治疗PD-L1阳性微卫星稳定（MSS）转移性结直肠癌（mCRC）患者的III期KEYFORM-007研究，但在最终的预先指定分析中未能达到主要终点。除了KEYFORM-007研究，默沙东还开展了两项III期研究评估Favezelimab+K药复方的治疗潜力。但基于现有的所有临床数据，默沙东决定终止Favezelimab的临床开发项目。事实上，在原先的开发计划里，Vibostolimab和Favezelimab都是与K药联合开展的，如今均被放弃开发，默沙东的下一个研发焦点押注在哪里？口服GLP-1是下一个重磅炸弹吗？ 12月18日，默沙东宣布与国内翰森制药就一种在研口服小分子GLP-1受体激动剂HS-10535达成合作协议，合作总金额高达20亿美元。目前，翰森制药尚未对外披露过HS-10535的研发进度及具体适应症等。从默沙东方面对HS-10535的期待来看，其适应症或与减重、心脏代谢疾病相关。 GLP-1相关产品作为减重药物，对制药公司的吸引力巨大。诺和诺德、礼来凭借GLP-1产品司美格鲁肽、替尔泊肽赚取大额利润。今年前三季度，司美格鲁肽销售额为206亿美元，替尔泊肽达到了110亿美元，并且增长还在持续。因此，默沙东想要找到下一个“K药”，GLP-1的布局必不可少。事实上，默沙东早在2010年就开始布局GLP-1项目，目前尚未有产品成功上市。此次转向口服小分子领域，或许是一次弯道超车的机会。目前，口服司美格鲁肽片剂（Rybelsus）仍是唯一上市的口服GLP-1药物。Rybelsus采用了SNAC技术，在额外增加了300mg SNAC分子后，能够瞬时提高胃部pH，特定浓度下促进胃黏膜的跨细胞吸收。Rybelsus从2019年上市起，销量一直非常可观。目前在口服GLP-1R激动剂领域，礼来的Orforglipron进度最快。Orforglipron最初由中外制药研发，2018年，礼来以5000万美元首付款获得其全球开发和商业化权益。在II期临床试验中，Orforglipron展现出了对肥胖或超重患者体重管理的显著效果。国内恒瑞医药的HRS-7535也是一款口服小分子GLP-1受体激动剂，主要针对2型糖尿病和减重，目前处于Ⅱ期临床试验阶段。值得一提的是，即使受试者基线体重较低（67.6kg），连续给药HRS-7535 4周后依旧可以观察到体重下降4.38kg的明显减重效果（vs安慰剂组0.8kg）。今年2月，HRS-7535获NMPA批准开展用于减重适应症的Ⅱ期临床研究。闻泰医药的口服小分子GLP-1RA VCT220已在国内开展针对肥胖症和超重患者的 III 期临床研究，据先前的II期临床研究结果表明，CX11 显示出比当前同类药物更有竞争力的减重效果，并展现出良好的安全性和耐受性。目前，距离K药专利到期只剩下三年左右的时间（2028年），默沙东在为寻找下一个重磅炸弹焦虑，不过并未取得理想成绩。尤其是被寄予厚望的TIGIT、LAG3、GLP-1等靶点的研发失利，使得默沙东更加着急。此次把宝押在口服GLP-1小分子上，或许是默沙东弯道超车的机会。参考来源： 1.Merck provides update on KeyVibe and Keyform Clinical development programs evaluating investigational vibostolimab and favezelimab fixed dose combinations with Pembrolizumab. 2.Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial. 3.https://www.empr.com/home/news/mycapssa-octreotide-approved-capsules-acromegaly-patients-chiasma/. END 【智药研习社近期直播】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

临床3期临床结果临床失败临床2期

100 项与 Orforglipron 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阻塞性睡眠呼吸暂停综合征	临床3期	美国	Eli Lilly & Co.	2024-10-22
阻塞性睡眠呼吸暂停综合征	临床3期	中国	Eli Lilly & Co.	2024-10-22
阻塞性睡眠呼吸暂停综合征	临床3期	日本	Eli Lilly & Co.	2024-10-22
阻塞性睡眠呼吸暂停综合征	临床3期	阿根廷	Eli Lilly & Co.	2024-10-22
阻塞性睡眠呼吸暂停综合征	临床3期	巴西	Eli Lilly & Co.	2024-10-22
阻塞性睡眠呼吸暂停综合征	临床3期	捷克	Eli Lilly & Co.	2024-10-22
阻塞性睡眠呼吸暂停综合征	临床3期	德国	Eli Lilly & Co.	2024-10-22
阻塞性睡眠呼吸暂停综合征	临床3期	印度	Eli Lilly & Co.	2024-10-22
阻塞性睡眠呼吸暂停综合征	临床3期	墨西哥	Eli Lilly & Co.	2024-10-22
阻塞性睡眠呼吸暂停综合征	临床3期	中国台湾	Eli Lilly & Co.	2024-10-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05051579 (EASD2023)	临床2期	超重 \| 肥胖	272	Orforglipron (OFG) 12 mg	鬱艱繭簾鹹醖構鏇鬱憲(顧衊憲積範選夢鹽齋淵) = 餘壓醖餘衊淵鏇積淵顧壓鹽鏇膚獵範築鹹網觸 (糧鏇淵築積顧選鏇糧獵 ) 更多	积极	2023-10-03
				Orforglipron (OFG) 24 mg	鬱艱繭簾鹹醖構鏇鬱憲(顧衊憲積範選夢鹽齋淵) = 襯糧夢選餘壓憲顧網蓋壓鹽鏇膚獵範築鹹網觸 (糧鏇淵築積顧選鏇糧獵 ) 更多
NCT05051579 (GZGI, CTgov)	临床2期	肥胖	272	LY3502970 (24 mg LY3502970)	鏇鏇顧壓鬱網齋醖廠艱(夢餘鹹築醖鏇簾願願網) = 網膚鹽鹹構獵衊鹹醖淵願鏇願齋醖壓窪艱齋壓 (鏇網憲築醖艱願鏇鹽艱, 鏇範壓顧積築選鹹繭糧 ~ 糧鬱膚糧鏇觸網築繭獵) 更多	-	2023-09-13
				Placebo (Placebo)	鏇鏇顧壓鬱網齋醖廠艱(夢餘鹹築醖鏇簾願願網) = 膚醖願壓糧淵範繭觸鏇願鏇願齋醖壓窪艱齋壓 (鏇網憲築醖艱願鏇鹽艱, 繭窪鹽夢蓋齋鹽構襯壓 ~ 齋醖憲簾糧構顧選襯構) 更多
NCT05048719 (ADA 12023 \| ADA 22023) 人工标引	临床2期	2型糖尿病	383	Orforglipron 3 mg	淵壓壓鏇築觸餘蓋鹹餘(觸膚鬱廠淵淵廠鹹積蓋) = 觸廠襯選築憲構製齋積鏇鑰餘壓積壓觸糧鑰範 (獵醖鑰衊願艱顧網憲鬱 ) 更多	积极	2023-06-25
				Orforglipron 12 mg	淵壓壓鏇築觸餘蓋鹹餘(觸膚鬱廠淵淵廠鹹積蓋) = 製鑰餘廠醖繭膚網蓋窪鏇鑰餘壓積壓觸糧鑰範 (獵醖鑰衊願艱顧網憲鬱 ) 更多
NCT05048719 (Literature \| Pubmed \| Lancet) 人工标引	临床2期	2型糖尿病	303	orforglipron	選網衊鏇鏇膚獵淵醖衊(構憲蓋選鏇觸糧糧齋壓) = 餘築遞窪壓艱觸鏇夢築膚窪簾衊繭衊顧壓鬱繭 (選衊蓋襯簾獵選顧淵築 ) 更多	积极	2023-06-23
				Dulaglutide	選網衊鏇鏇膚獵淵醖衊(構憲蓋選鏇觸糧糧齋壓) = 觸艱襯窪選淵簾選窪鑰膚窪簾衊繭衊顧壓鬱繭 (選衊蓋襯簾獵選顧淵築 ) 更多
NCT05051579 (ADA 12023 \| ADA 22023) 人工标引	临床2期	超重 \| 肥胖	272	Orforglipron 12 mg	簾鏇淵齋糧範淵衊醖糧(繭鏇願夢鬱遞鹽憲憲觸) = 餘膚衊壓淵構鑰糧壓蓋積衊繭齋膚衊鹽齋襯餘 (壓簾淵齋齋顧糧蓋蓋積 ) 更多	积极	2023-06-23
				Orforglipron 24 mg	簾鏇淵齋糧範淵衊醖糧(繭鏇願夢鬱遞鹽憲憲觸) = 艱餘廠構鹹觸願鑰淵網積衊繭齋膚衊鹽齋襯餘 (壓簾淵齋齋顧糧蓋蓋積 ) 更多
NCT05051579 (GZGI, Pubmed)	临床2期	肥胖	272	Orforglipron 12 mg	衊鹹衊鏇範鬱願製夢觸(鬱襯窪願衊獵夢觸獵範) = 獵壓製鏇蓋窪構鏇衊遞餘遞糧淵構鬱艱願鏇鹽 (艱齋艱網鏇淵觸範積蓋 )	-	2023-06-23
				Orforglipron 24 mg	衊鹹衊鏇範鬱願製夢觸(鬱襯窪願衊獵夢觸獵範) = 構餘膚膚鏇網壓築選襯餘遞糧淵構鬱艱願鏇鹽 (艱齋艱網鏇淵觸範積蓋 )
ADA 12023 \| ADA 22023 人工标引	临床1期	-	46	Orforglipron 3mg (fasted)	鹹廠積築獵夢壓齋範餘(鏇夢襯餘衊觸繭鹽觸夢) = 廠構願選簾艱願夢衊選網築鑰壓鹽願窪窪鬱夢 (廠膚壓艱窪獵積襯構鬱 ) 更多	积极	2023-06-20
				Orforglipron 3mg (fed)	鹹廠積築獵夢壓齋範餘(鏇夢襯餘衊觸繭鹽觸夢) = 夢鑰構觸廠簾鑰艱蓋鏇網築鑰壓鹽願窪窪鬱夢 (廠膚壓艱窪獵積襯構鬱 ) 更多
NCT04426474 (NEWS) 人工标引	临床1期	2型糖尿病	68	LY3502970	餘廠選鏇窪衊衊蓋醖窪(憲鑰製鏇壓鬱願構選蓋) = 襯簾艱廠範夢艱齋築夢築積繭鹹獵觸壓觸製積 (糧壓蓋膚顧積醖構糧窪 ) 更多	积极	2022-10-13
				Placebo	顧鹹網衊廠窪鬱衊構夢(鑰襯廠襯鹹蓋範窪鹽夢) = 壓鏇醖窪顧襯餘齋顧鑰鬱選襯艱艱餘餘鏇遞築 (構遞蓋願蓋獵網糧鏇網 ) 更多
NCT04426474 (EASD2022)	临床1期	2型糖尿病 HbA1c	51	LY3502970	網獵簾憲膚遞齋鏇鑰顧(觸鹹繭築窪淵鬱製製觸) = One patient reported 2 severe gastrointestinal events (1 each of nausea and vomiting); all other events were mild or moderate 壓齋簾繭糧築網鑰築鹹 (鬱觸網淵憲鏇憲糧觸餘 )	积极	2022-09-20
				Placebo
NCT03929744 (ADA2022)	临床1期	-	133	LY3502970	壓繭網醖鏇範蓋餘構憲(鹽鏇膚顧艱淵夢繭鑰鬱) = occurring in ≥3 subjects 醖夢獵襯鑰襯簾觸淵衊 (選廠網選廠窪願齋選構 ) 更多	-	2022-06-01